Immuneering to Present at Leerink Global Healthcare Conference

The late-stage clinical oncology company will discuss its pipeline, platform, and business strategy.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Immuneering Corporation, a late-stage clinical oncology company, announced that its CEO Ben Zeskind will present at the Leerink Global Healthcare Conference in Miami, Florida from March 9-11, 2026. The presentation will focus on the company's pipeline, platform, and business strategy.

Why it matters

As a late-stage clinical oncology company, Immuneering's presentation at the prestigious Leerink Global Healthcare Conference provides an opportunity to showcase its progress and attract potential investors and partners to support the development of its innovative cancer treatments.

The details

Immuneering's presentation will take place on Monday, March 9, 2026, from 3:40 - 4:10 pm ET. The company's lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Immuneering expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients.

  • Immuneering's presentation will take place on Monday, March 9, 2026, from 3:40 - 4:10 pm ET.
  • Immuneering expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients.

The players

Immuneering Corporation

A late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive.

Ben Zeskind

Chief Executive Officer of Immuneering Corporation.

Got photos? Submit your photos here. ›

What they’re saying

“Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive.”

— Ben Zeskind, Chief Executive Officer (Immuneering Corporation)

What’s next

Immuneering expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients.

The takeaway

Immuneering's presentation at the Leerink Global Healthcare Conference is a significant milestone for the company as it showcases its progress in developing innovative cancer treatments and seeks to attract potential investors and partners to support its continued growth and development.